Castle Biosciences (CSTL) Total Current Liabilities (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Total Current Liabilities data on file, last reported at $48.8 million in Q1 2026.

• Quarterly Total Current Liabilities rose 30.82% year-over-year to $48.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.8 million (up 30.82% YoY) and the FY2025 annual result came in at $68.7 million, up 39.04% from the prior year.
• Total Current Liabilities eased to $48.8 million in Q1 2026 per CSTL's latest filing, from $68.7 million in the prior quarter.
• The five-year high for Total Current Liabilities was $68.7 million in Q4 2025, with the low at $27.5 million in Q2 2022.
• Average Total Current Liabilities over 5 years is $41.7 million, with a median of $39.5 million recorded in 2024.
• Year-over-year, Total Current Liabilities jumped 124.83% in 2022 and declined 23.73% in 2023.
• Castle Biosciences' Total Current Liabilities stood at $36.1 million in 2022, then surged by 31.94% to $47.7 million in 2023, then climbed by 3.62% to $49.4 million in 2024, then surged by 39.04% to $68.7 million in 2025, then fell by 29.0% to $48.8 million in 2026.
• Business Quant data shows CSTL's Total Current Liabilities at $48.8 million in Q1 2026, $68.7 million in Q4 2025, and $55.3 million in Q3 2025.